The FDA granted a Fast Track designation (FTD) to the humanized PD-1 monoclonal antibody toripalimab for the first-line treatment of patients with mucosal melanoma, announced Junshi Biosciences, in a press release.1
Publications
Oncotarget: Improved therapeutic efficacy of unmodified anti-tumor antibodies
The cover for issue 2 of Oncotarget features Figure 4, “Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in “Improved therapeutic efficacy of unmodified anti-tumor antibodies….
OAM recipient dedicates honour to those lost to skin cancer
Melanoma Man’ Jay Allen has been recognised for his commitment to skin cancer awareness, today awarded a Medal of the Order of Australia.
Study Identifies Shift in Incidence of Second Primary Cancers in Patients with Metastatic Melanoma
A study published in JAMA Network Open observed a shift in the incidence of second primary cancers after metastatic melanoma that specifically changed during the age of immune checkpoint inhibitors (ICIs) and most commonly manifesting as cancers of the small intestine and myeloma.